search returned 100 results for adalimumab, showing results 71 to 80
, adalimumab, baricitinib, certolizumab, etanercept,
golimumab, infliximab, rituximab, tofacitinib, and upadacitinib) and for the treatment of severe
active juvenile idiopathic arthritis (adalimumab
https://rheumatology.org.au/LinkClick.aspx?fileticket=3mFHqV%2fIUZc%3d
, adalimumab, baricitinib, certolizumab, etanercept,
golimumab, infliximab, rituximab, tofacitinib, and upadacitinib) and for the treatment of severe
active juvenile idiopathic arthritis (adalimumab
https://rheumatology.org.au/LinkClick.aspx?fileticket=3mFHqV_IUZc%3d&portalid=2
.
Patient Case: An elderly patient had their adalimumab continued by the GP even though they
had
https://rheumatology.org.au/LinkClick.aspx?fileticket=g1dgPg0JoqU%3d
(S100 Private) 14505
2
nd
or subsequent continuing RA adalimumab, baricitinib
https://rheumatology.org.au/LinkClick.aspx?fileticket=ZAU2LIEG1W4%3d
.
Patient Case: An elderly patient had their adalimumab continued by the GP even though they
had
https://rheumatology.org.au/LinkClick.aspx?fileticket=g1dgPg0JoqU%3d&portalid=2
to the board to reconsider the prescribing of
methotrexate by NP’s.
12.2 Adalimumab for uveitis...) and they are looking to make a submission to the
PBAC to get adalimumab on the PBS for uveitis
• Most patients with uveitis needing biologic treatment access adalimumab
through the AbbVie
https://rheumatology.org.au/LinkClick.aspx?fileticket=CkmP68G9H2I%3d
to the board to reconsider the prescribing of
methotrexate by NP’s.
12.2 Adalimumab for uveitis...) and they are looking to make a submission to the
PBAC to get adalimumab on the PBS for uveitis
• Most patients with uveitis needing biologic treatment access adalimumab
through the AbbVie
https://rheumatology.org.au/LinkClick.aspx?fileticket=q89m8IGnttE%3d
, etanercept, rituximab
• Currently approved, not yet in market- adalimumab (more than one biosimilar brand)
• Infliximab, etanercept and adalimumab biosimilars have been deemed by the PBAC... this driver to also become available for biosimilar forms of adalimumab,
when they come to market
https://rheumatology.org.au/LinkClick.aspx?fileticket=iGlXjRQofaA%3d
to the board to reconsider the prescribing of
methotrexate by NP’s.
12.2 Adalimumab for uveitis...) and they are looking to make a submission to the
PBAC to get adalimumab on the PBS for uveitis
• Most patients with uveitis needing biologic treatment access adalimumab
through the AbbVie
https://rheumatology.org.au/LinkClick.aspx?fileticket=CkmP68G9H2I%3d&portalid=2
Considerations
Tocilizumab IV
80mg/4mL
RA Yes Yes Multiple
Polyarticular JIA Yes Yes Adalimumab... Yes Multiple
Polyarticular JIA Yes Yes Adalimumab
Etanercept
Systemic JIA Yes No Anakinra... Adalimumab
Etanercept
Systemic JIA Yes No Anakinra
Canakinumab
Alternatives not available
https://rheumatology.org.au/LinkClick.aspx?fileticket=TT0Q1OW8ERI%3d